Symbol | Exchange | Currency |
|---|
Investing.com – U.S. stocks were mixed after the close on Friday, as gains in the Technology, Healthcare and Telecoms sectors led shares higher while losses in the Financials, Oil...
Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Oil & Gas, Consumer Services and Financials sectors led shares lower. At the close in NYSE,...
Investing.com – U.S. stocks were lower after the close on Wednesday, as losses in the Oil & Gas, Basic Materials and Consumer Goods sectors led shares lower. At the close in NYSE,...
Biotech has been a hot area in this market. Whether large cap or small cap, Wall Street and Main Street have watched as biotech companies have surged. This is partly due to the...
Arca Biopharma (ABIO) was a very boring ticker in 2013 until the company provided an update on a proposed clinical trial for a trial fibrillation for the company’s flagship...
Small cap stocks continue their hot streak. The January Effect continues in 2013. Each day another few small caps soar higher, leaving the ground, headed for the stratosphere. The...
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company, which is focused on development and commercialization of targeted therapies for cardiovascular diseases. The Company's lead product includes Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) and Gencaro (bucindolol hydrochloride). rNAPc2 (AB201) is a treatment for diseases caused by ribonucleic acid (RNA), viruses, focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus. The gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties for the treatment of atrial fibrillation (AF) in patients with heart failure. The Company is conducting Phase II b clinical trial of rNAPc2 (AB201). Its ASPEN-COVID-19 Phase IIb is a randomized, multi-center, international clinical trial evaluating two dose regimens of rNAPc2 versus heparin prescribed per local standard of care in hospitalized SARS-CoV-2 positive patients that also have an elevated D-dimer level.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Sell | Neutral | Buy | Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Buy | Strong Sell |
| Summary | Strong Sell | Strong Sell | Sell | Strong Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 166.33 | 168.45 | 166.20 | -0.02 | -0.01% | 1.32M | NASDAQ | |||
| 110.81 | 113.04 | 109.53 | +3.85 | +3.60% | 1.41M | NYSE | |||
| 81.11 | 86.73 | 81.01 | -5.05 | -5.86% | 47.98M | NASDAQ | |||
| 104.29 | 114.05 | 104.08 | -6.21 | -5.62% | 18.24M | NYSE | |||
| 7.83 | 7.91 | 7.82 | -0.12 | -1.45% | 2.93M | NASDAQ | |||
| 13.51 | 13.85 | 13.38 | 0.00 | 0.00% | 2.53M | OTC Markets | |||
| 3.392 | 3.68 | 3.39 | -0.218 | -6.05% | 3.43M | NYSE | |||
| 7.70 | 8.17 | 7.70 | -0.39 | -4.82% | 2.16M | NYSE | |||
| 220.21 | 221.63 | 218.25 | +3.00 | +1.38% | 204.96K | NASDAQ | |||
| 36.33 | 37.28 | 36.24 | +0.67 | +1.88% | 3.22M | NYSE | |||
| 63.45 | 64.59 | 63.45 | +0.43 | +0.68% | 1.75M | NYSE | |||
| 1.06 | 1.121 | 1.06 | -0.0400 | -3.64% | 1.58M | NYSE | |||
| 0.1253 | 0.1386 | 0.1221 | -0.0124 | -9.01% | 849.66K | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 49.13 | 50.40 | 49.13 | -0.94 | -1.88% | 680.20K | NYSE |